Kesimpta

OTHER3 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Active Secondary Progressive Multiple SclerosisMultiple SclerosisPregnancyRelapsing-remitting Multiple Sclerosis

Unknown Phase

Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen

CompletedNCT04940065

Novartis PharmaceuticalsActive Secondary Progressive Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis

Start: 2021-06-30End: 2024-12-12Updated: 2025-11-28

A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis

CompletedNCT05334472

Novartis PharmaceuticalsMultiple Sclerosis

Start: 2021-11-24End: 2023-02-15Updated: 2024-03-25

Kesimpta (Ofatumumab) Pregnancy Registry

RecruitingNCT05634967

Novartis PharmaceuticalsMultiple Sclerosis, Pregnancy

Start: 2023-01-05End: 2033-02-28Target: 725Updated: 2025-01-14